Storia in 5 fonti

Novo Nordisk gets a downgrade from Bank of America as Wegovy growth outlook weakens

The bank downgraded the Danish pharmaceutical giant to neutral from buy and decreased its price target.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

cnbc.comStai leggendo11 mesi fa

Novo Nordisk gets a downgrade from Bank of America as Wegovy growth outlook weakens

The bank downgraded the Danish pharmaceutical giant to neutral from buy and decreased its price target.

originale

Timeline cronologica

martedì 29 luglio 2025·cincodias.elpais.com
Novo Nordisk se desploma en Bolsa tras reducir de nuevo sus previsiones sobre Ozempic y Wegovy para este año
La farmacéutica danesa espera un crecimiento menor, lo que supone su segundo recorte de estimaciones en lo que va de año
martedì 29 luglio 2025·cnbc.com
Novo Nordisk shares plunge after Wegovy maker names new CEO, cuts full-year guidance
Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance.

ilsole24ore.com

11 mesi fa

Novo Nordisk crolla a Copenaghen. Abbassa previsioni a causa del mercato Usa

Le nuove previsioni di vendita per il 2025, previste tra l'8 e il 14%, sono dovute a minori aspettative di crescita per la seconda metà dell’anno.

Leggi questa versione → originale

bbc.com11 mesi fa

Wegovy maker Novo Nordisk warns of slower profits as rivals bite

The Danish weight loss drug-maker claims "knock-off" treatments are hitting growth.

Leggi questa versione → originale

npr.org11 mesi fa

Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

Leggi questa versione → originale

cincodias.elpais.com11 mesi fa

Novo Nordisk se desploma en Bolsa tras reducir de nuevo sus previsiones sobre Ozempic y Wegovy para este año

La farmacéutica danesa espera un crecimiento menor, lo que supone su segundo recorte de estimaciones en lo que va de año

Leggi questa versione → originale

martedì 29 luglio 2025·

ilsole24ore.com

Novo Nordisk crolla a Copenaghen. Abbassa previsioni a causa del mercato Usa

Le nuove previsioni di vendita per il 2025, previste tra l'8 e il 14%, sono dovute a minori aspettative di crescita per la seconda metà dell’anno.

martedì 29 luglio 2025·

bbc.com

Wegovy maker Novo Nordisk warns of slower profits as rivals bite

The Danish weight loss drug-maker claims "knock-off" treatments are hitting growth.

martedì 29 luglio 2025·

npr.org

Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to…

mercoledì 30 luglio 2025·

cnbc.com

Novo Nordisk gets a downgrade from Bank of America as Wegovy growth outlook weakens

The bank downgraded the Danish pharmaceutical giant to neutral from buy and decreased its price target.

mercoledì 30 luglio 2025·

cnbc.com

Novo Nordisk's stock plunge isn't surprising. Why companies clear the deck for new CEOs

Renault, Elekta, Tietoevry and a number of others have recently reset expectations with investors.

Novo Nordisk gets a downgrade from Bank of America as Wegovy growth outlook weakens

Timeline cronologica

Novo Nordisk se desploma en Bolsa tras reducir de nuevo sus previsiones sobre Ozempic y Wegovy para este año

Novo Nordisk shares plunge after Wegovy maker names new CEO, cuts full-year guidance

Novo Nordisk crolla a Copenaghen. Abbassa previsioni a causa del mercato Usa

Wegovy maker Novo Nordisk warns of slower profits as rivals bite

Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding

Novo Nordisk se desploma en Bolsa tras reducir de nuevo sus previsiones sobre Ozempic y Wegovy para este año

Novo Nordisk crolla a Copenaghen. Abbassa previsioni a causa del mercato Usa

Wegovy maker Novo Nordisk warns of slower profits as rivals bite

Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding

Novo Nordisk gets a downgrade from Bank of America as Wegovy growth outlook weakens

Novo Nordisk's stock plunge isn't surprising. Why companies clear the deck for new CEOs